Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma

Clinical Trial ID NCT04387500

Rank	Title	Journal	Year	PubWeight™‹?›
1	Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.	Nat Genet	2002	8.19
2	Reductive carboxylation supports growth in tumour cells with defective mitochondria.	Nature	2011	6.57
3	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.	Cancer Cell	2005	5.47
4	An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.	Cancer Cell	2011	2.78
5	Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.	J Immunol	2008	1.63
6	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.	J Clin Oncol	2016	1.43
7	Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.	Nat Commun	2016	0.75
8	Myeloid derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL-1β, IL-8, CXCL5 and Mip-1α.	Clin Cancer Res	2016	0.75